title: Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia.
abstract: OBJECTIVE
  To evaluate bone mineral density (BMD) in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia (CAH).
  
  
  METHODS
  A relationship between bone mineral content and risk for osteoporotic fractures has been observed in adulthood. Infancy, childhood, and adolescence are critical periods for skeletal mineralization; thus, chronic diseases may impair bone mass peaking, particularly if children and adolescents are overexposed to glucocorticoids, as may occur in patients with CAH. Lumbar L2-L4 BMD values were measured by dual x-ray absorptiometry and compared with those of 471 age- and sex-matched controls.
  
  
  METHODS
  Thirty-three patients with the salt-wasting form of CAH were studied. Sixteen (10 girls and 6 boys; age range, 1.5 to 8.3 years) were prepubertal and 17 (13 women and 4 men; age range, 17.1 to 28.2 years) were adolescent and young adults who had reached final height and had presented normal pubertal development and normal gonadal function thereafter. The average doses of hydrocortisone (mg/m body surface/day) received from diagnosis in the neonatal period to BMD evaluation were 21.2 +/- 2.2 and 22.3 +/- 2.6, respectively.
  
  
  RESULTS
  Mean BMD Z score values were 0.16 +/- 1.01 in prepubertal patients and 0.06 +/- 1.02 in adolescent and young adult patients with no statistically significant differences with age- and sex-matched controls. Mean height Z score values were -0.03 +/- 1.13 in prepubertal patients and -1.13 +/- 0.62 in adolescent and young adult patients with significant differences between the latter and their respective age- and sex-matched controls.
  
  
  CONCLUSIONS
  Long-term glucocorticoid therapy does not impair bone mass peaking in CAH patients with normal gonadal function, even though their adult height values are low.
authors.affiliation: Department of Pediatrics, Children's Hospital Vall d' Hebron, Autonomous University, Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Gussinyé
authors.forename: A
authors.initials: A
authors.lastname: Carrascosa
authors.forename: N
authors.initials: N
authors.lastname: Potau
authors.forename: M
authors.initials: M
authors.lastname: Enrubia
authors.forename: E
authors.initials: E
authors.lastname: Vicens-Calvet
authors.forename: L
authors.initials: L
authors.lastname: Ibáñez
authors.forename: D
authors.initials: D
authors.lastname: Yeste
mesh_terms: D000293:Adolescent; D000312:Adrenal Hyperplasia, Congenital / Q000188:drug therapy / Q000503:physiopathology*; D000328:Adult; D001827:Body Height; D015519:Bone Density / Q000187:drug effects; D002113:Calcification, Physiologic; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology / Q000627:therapeutic use; D007223:Infant; D008297:Male
chemical_list: D006854:Hydrocortisone